Actinium Pharmaceuticals, Inc. (ATNWW) financial statements (2020 and earlier)

Company profile

Business Address 275 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1417212676
Cash and cash equivalents 1417212676
Prepaid expense  0111 
Deposits current assets     0 
Other undisclosed current assets 1010 0
Total current assets: 1418222676
Noncurrent Assets
Property, plant and equipment 000000
Restricted cash and investments  0  0 
Other undisclosed noncurrent assets 000   
Total noncurrent assets: 100000
TOTAL ASSETS: 1518232786
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 65412 
Other undisclosed accounts payable and accrued liabilities 65412 
Debt 0  000
Derivative instruments and hedges, liabilities  00377
Due to related parties  0000 
Other undisclosed current liabilities      0
Total current liabilities: 655597
Noncurrent Liabilities
Long-term debt and lease obligation 0     
Capital lease obligations0     
Total noncurrent liabilities: 0     
Total liabilities: 655597
Stockholders' equity
Stockholders' equity attributable to parent, including: 9141822(2)(2)
Common stock 000000
Additional paid in capital 1961771551348965
Accumulated deficit (187)(163)(137)(112)(91) 
Other undisclosed stockholders' equity attributable to parent      (67)
Total stockholders' equity: 9141822(2)(2)
TOTAL LIABILITIES AND EQUITY: 1518232786

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Operating expenses (24)(27)(27)(25)(22)(7)
Operating loss: (24)(27)(27)(25)(22)(7)
Nonoperating income (expense) 0034(2)(4)
Interest and debt expense   (0)(0)(0)(0)
Net loss: (24)(27)(24)(21)(25)(11)
Other undisclosed net income attributable to parent   0000
Net loss available to common stockholders, diluted: (24)(27)(24)(21)(25)(11)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (24)(27)(24)(21)(25)(11)
Comprehensive loss, net of tax, attributable to parent: (24)(27)(24)(21)(25)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: